In the current study, although we have not confirmed the presentation of FGFR3Y373C on other HLA-A02 molecules, FGFR3Y373C might be able to induce specific CD8+ T cells in individuals carrying other HLA-A*02 alleles, suggesting the possibility that FGFR3Y373C is available as the target shared neoantigen for a wider range of bladder cancer patients. This evidence concerns the gene CD8A and urinary bladder carcinoma.